Alright folks, here's the deal… Today's alert could become our BIGGEST RIPPER yet this week as we aim to go 3-0 on winning alerts with MOLOF! Strap in and get focused, because you might be witness to a lightning bolt today at the opening bell!
 

 

Molori Energy ("Molori" or the "Company") currently owns a 25 percent working interest in certain leases located in the bifurcated Texas panhandle owned by Texas-based independent oil and gas producer Ponderosa Energy, LLC ("Ponderosa").
?
Today, the Company has 165 producing (PDP) wells and an inventory of approximately 202 non-producing wells (PDNP) for a total of 367 wells. The Company will RTP ("Return To Production") the PDNP wells by performing simple re-works or re-completions which will include among other actions: replacing broken rods/tubing, steaming paraffin, performing chemical and acid treatments, repairing mechanical issues on pumpjacks, repairing flowlines, and  repairing electricity and salt water disposal infrastructure. As a result, the Company has realized an average workover expense per well of approximately USD $12,000. These RTPs have demonstrated average production increases of 2.4 boepd/PDNP, resulting in an average cost per flowing bbl of USD $5,000/flowing BBL.  When the assets were acquired in June 2016, the aggregate 8/8ths production was 40 BOEPD.  As of February 2017, production increased to 435 BOEPD through the RTP program and acquisitions.

The assets include low-decline, PDP weighted reserves primarily in the West Panhandle Field of the Hugoton Basin of Texas. The assets are approximately 50% oil and 50% liquid rich gas (HIGH BTU premium gas)  primarily located in Carson, Gray, and Hutchinson Counties of District 10.

??The approximately 24,000 net acres currently owned by Molori Energy are all held by production. Molori Energy implemented a consolidation strategy to aggregate large leaseholds with inactive wells containing economic reserves, all with low decline rates, and low geological risk. As the Company returns to production these wells, it leverages economies of scale from shared infrastructure and overhead to reduce the lease operating expenses per boe.

 

 

Working Interest Partners

 

The latest NI 51-101 reserve report commissioned by Molori and effective January 1, 2017, covers 66 of the leases in which Molori holds a working interest. Work is ongoing in a further 13 leases owned by Molori and Ponderosa, but not covered by this report. It is anticipated that the leases not covered by this report will constitute part of the next NI 51-101 presently being prepared on behalf of Molori and Ponderosa.

In summary, the initial projected average production was 40 barrels of oil equivalent per day ("BOEPD")* in June 2016, when Molori made its first investment into Ponderosa.  For the month of January 2017, production averaged 280 BOEPD, a 600% increase in daily average production. This production increase is due primarily to an aggressive work-over plan employing working capital committed by Molori to return non-producing wells to production, while keeping Lease Operating Expenses low due to tight cost controls and already established management.

Further, the initial NI 51-101 dated April 1, 2016 resulted in USD$5.15 million of 1P (Total Proven Reserves) consisting of US$1.25 million PDP (Proved Developed Producing) and USD$2.89 million PDNP (Proved Developed non-Producing).  The new updated NI 51- 101 dated March 08, 2017, effective January 2017 and prepared by Amiel David, Ph.D of PeTech Enterprises Inc, has resulted in USD$26.9 million 1P (Total Proven Reserves), a 420% increase, including USD$16.26 million in PDP and US$10.65 million PDNP. The resulting increase is a result of a successful work-over plan, and the fact that Ponderosa had as many as 10 work-over rigs employed during much of that time.

– All numbers are in USD
– Molori Interest is 25%

* Per BOE amounts have been calculated by using the conversion ratio of six thousand cubic feet (6 MCF) of natural gas to one barrel (1 bbl) of crude oil. The BOE conversion ratio of 6 mcf to 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given that the value ratio based on the current price of natural gas as compared to oil is significantly different from the energy equivalent of 1:6, utilizing a conversion on a 1:6 basis may be misleading as an indication of value. The ratio of gas to oil was 70% gas and 30% oil in June 2016 and 40% gas and 60% oil in January 2017.

 

 

???????Red Cave Opportunity

 

Molori’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to generate steady cash flows. Over 60 wells have been reactivated to date, producing from the prolific Brown Dolomite formation. Molori and Ponderosa have generated USD$16 MM NPV-9% of discounted cash flows from this strategy with USD$2.5 MM of capital investment including infrastructure. The low-risk recompletion strategy has given Molori the opportunity to pivot into higher-growth strategies.

Ponderosa and Molori have identified a development opportunity in the Red Cave formation. The formation is prevalent throughout its leases at a shallower depth of 2,100’ to 2,300’. Improved fracing technologies and completion techniques have demonstrated the Red Cave to be an economic development target. The Red Cave has been developed since the 1950’s but was not considered to be a high value target because of inadequate historical technology. Similar to the Permian Basin, new technologies have unlocked the reservoir to generate economic reserves and production in present day.

Molori has aggregated acreage in the play and will continue to add inventory in the coming months. After reaching further milestones in the Brown Dolomite reactivation strategy, the combined companies will test development to the Red Cave zone,  which if successful, will add hundreds of economic drilling locations to the already robust inventory of PDNP wells.

???????

 

Texas Hugoton & Panhandle Field

 

On June 6, 2016, Molori Energy Inc closed on the purchase of a 25% working interest in the oil and gas production from certain leases owned by Texas-based Ponderosa Energy, LLC. In conjunction with the purchase (see Molori Energy Inc. press release dated June 2, 2016), Molori committed USD $1,000,000 in working capital towards a program to complete workovers on the Texas-based leases in order to increase production.

Ponderosa, a domestic USA oil and gas production company, is the operator on the leases and is presently focused on aggregating and developing shallow, conventional oil reserves in Texas.

Ponderosa originally purchased these leases from distressed operators with highly-leveraged balance sheets and an inability to fund operations.

Molori and Ponderosa have chosen to collectively pursue assets which specifically exhibit the following properties: shallow reservoir, low geologic risk, moderate decline rates, and existing infrastructure.

The focus of Molori and Ponderosa’s activities has been in the “Hugoton-Panhandle” field in Northern Texas.

The Hugoton-Panhandle field, was the largest gas field in North America until the development of unconventional shale. The Anadarko Basin, which houses the Hugoton-Panhandle field, has produced over 125 trillion cubic feet of gas and 5.4 billion barrels of oil. Since the discovery of the Hugoton-Panhandle field in 1922, thousands of wells have been drilled to date. Due to the vast historical drilling and production data, there is a low geological risk associated with oil and gas development. The maturity of the field is crucial to Molori’s strategy of building reserves and resources, as decline rates are typically under 5% (year over year). Lastly, the liquids rich natural gas in this area, commands a premium over spot gas pricing. For these reasons, Molori is focused upon buying additional assets in this area.

In aggregate, Molori has a 25% interest in the approximately 250 wells purchased by Ponderosa. Molori Energy Inc is continuing to back Ponderosa as it fulfills its operational obligations in redeveloping non-operating wells and bringing them back into production.

 

For more info, check out their website: http://www.molorienergy.com/

???????

 

Recent "GROUNDBREAKING" Developments:

 

Molori Energy's Thompson 23-1R Well Flows Oil

 

Borger, Texas–(Newsfile Corp. – February 22, 2018) – Molori Energy Inc. (TSXV: MOL) (OTCQB: MOLOF) ("Molori" or "the Company") is pleased to announce a commercial oil discovery on its acreage in Moore County, Texas.

 

The "Thompson 23-1R" well, operated by Molori Energy, is a northern step-out well drilled in December 2017 where Molori Energy holds a seventy five percent (75%) working interest via its Thompson 26 and Thompson T2 leases. These leases directly adjoin to leases owned and operated by Adams Affiliates of Tulsa, OK, a successful operator and producer in the Red Cave trend. The Thompson 23-1R well is directly north of the active development area of Adams Affiliates.

 

As announced previously, he 23-1R well was completed on January 22^nd, and was fractured with over 250,000 lbs sand and 340,000 gallons of slick water. The well has responded and produced on February 18th at 22 boepd*, 35 mcfd, and 61 bwpd for a blended production rate of approximately 28 boepd. The bulk of the water is load water which is consistently dropping with time, and the oil rate is steadily increasing with time. Peak production is expected within the next ten to fourteen days, following which Molori will be providing definitive results.

 

Furthermore, we have estimated that the reservoir pressure is 420 psia, which is consistent with original reservoir pressure in this area, and this location is not drained by offset production. The well log shows 100% oil pay with no gas cap. The log parameters are 37 feet of pay with 11.6% porosity with 39.8% Swi (Initial Water Saturation). These log results are very consistent with the near offset wells drilled recently by Adams Affiliates.

 

Commented Joel Dumaresq, CEO of Molori "We are extremely pleased with the 'discovery' and the initial results of our Thompson 23-1R well and frac into the Red Cave. The oil to water ratio continues to improve daily as we recover the water injected with the frac, and as a result we are experiencing daily increases in production."

 

Molori is expediting the installation of additional production tanks and moving forward with the continued development of its acreage in the area.

 

* Per BOE amounts have been calculated by using the conversion ratio of six thousand cubic feet (6 MCF) of natural gas to one barrel (1 bbl) of crude oil. The BOE conversion ratio of 6 mcf to 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given that the value ratio based on the current price of natural gas as compared to oil is significantly different from the energy equivalent of 1:6, utilizing a conversion on a 1:6 basis may be misleading as an indication of value. The ratio of gas to oil is 22% gas and 78% as reported.

 

CONTINUE READING THE FULL PRESS RELEASE HERE: https://www.newsfilecorp.com/release/33008/Molori-Energys-Thompson-231R-Well-Flows-Oil

 

 

 —————-

???????

Alright folks, here's the deal… Today's alert could become our BIGGEST RIPPER yet this week as we aim to go 3-0 on winning alerts with MOLOF! Strap in and get focused, because you might be witness to a lightning bolt at tomorrow's bell!

 

 

Earlier this week, I released NXTD and BPMX. Both plays delivered opportunities at potentially lucrative intra-day runs behind serious, serious volume. After researching multiple indicators, chart patterns, and news releases, I came to the conclusion that both picks had strong potential upside! In my opinion, MOLOF displays many of the same traits that turned NXTD and BPMX into monster runners!

 

 

Before we get too deep into the technicals, I want you to wrap your head around Molori Energy Inc. and why this company could have a extremely bright future!

 

If you didn't know, President Trump has had a PRO gas and oil agenda since he has taken office as he desires to push the U.S. towards a point of global dominance in the energy arena.

 

 

This article from Forbes.com explains why President Trump's energy agenda has been directly benefiting companies like Molori Energy who are firmly planted in the oil and gas industries.

 

Pair that news with the fact that oil prices hit their highest level in January since 2014 at $70/b, and a forecast of over $100/b by 2014, and we can acknowledge a company in this sector, like Molori Energy, could be in for an extremely bright future!

 

 

MOLOF, from a technical standpoint, could be a big time runner for several reasons… With technicals pointing to this alert as an undervalued play, and a chart with a past history of spiking, MOLOF could explode at tomorrow's bell!

 

 

Currently, MOLOF has an OVERSOLD 9-Day Relative Strength Index of 29.47% which means it could be do for a healthy reversal at tomorrow's bell as traders could see an opportunity to enter a play that is undervalued.

 

 

Take a look at MOLOF's 5-Day trading volume average as it has picked up significantly as it has been popping up on multiple radars. That 5-Day average of 84K shares is more than 2X its YTD daily average!

 

 

Remember, the last two winners we identified from this week ended up crushing monsters runs on the heels of significantly higher trading volume. Could a potential 3rd winner be born from that same scenario tomorrow?!?!

 

 

 With a 52-Week high of $.52, there is obvious room for growth in this OTCQB alert. Trading at current lows, a bounce back towards a fraction of those levels could provide traders with a potentially impressive ripper!

 

 

According to Barchart.com, MOLOF is displaying a BULLISH 20-50 Day MACD Oscillator which means upside momentum has been increasing and could pay off in a potential valuation spike in the near future!

 

Another OVERSOLD indicator we can look at is the Williams %R. Barchart also tells us that MOLOF's 9-Day %R is at a silly oversold level of 99.51%!

 

 

All of these indicators paint the picture of a dramatically oversold alert that could see a healthy reversal at any moment! Taking that into account while looking at the chart below, MOLOF could be in for an epic day of trading tomorrow as this known spiker could return to previous highs if today's momentum continues in the morning!

 

 

Take A Look @ The Chart Found Below Immediately To See For Yourself!

 

 

This ticker has DYNAMITE potential for short-term BLAST-OFFS! Don't forget, MOLOF is trading considerably under 52-Week highs!

 

(I am not guaranteeing that MOLOF will go flying to any previous high or beyond. To do so, would be irresponsible. Simply, I want you to be aware of MOLOF's potential upside through a thorough study of its technicals and chart.)

 

MOLOF could be a bouncer as it has on many occasions over the past year… Where could tomorrow's potential bounce take us?!?!

 

Take a close look at MOLOF'S CHART below immediately:

Do you see those short-term runs? Crazy, right? This play is an oversold ticking time bomb!

 

 

On September, 20 2017 (MOLOF) dropped to a low of $.3112. Over the next few sessions, MOLOF built steam to a high of $.5066 on September 26th. That multi-session push of +62% shows how electric this energy can be in the short-term and why you should get it on your radar now!

 

 

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided) 

 

 

All you need to look at are a couple key ingredients to understand why this pick could be explosive! Study all of the OVERSOLD indicators like MOLOF's RSI and Williams %R, along with its chart history, and be prepared at tomorrow's bell!

 

 

Could this bounce play lead to our third consecutive win this week? I wouldn't bring this alert to your attention if I didn't think it had tremendous potential upside like my previous two runners!

 

 

Do yourself a favor! Get this WIN STREAK STARTING BOUNCE MONSTER researched quickly, and get MOLOF on your radar before it's too late!

 

 

 

Make sure to always do your own research and due diligence on any day and swing trade alert I bring to your attention. I am not a licensed financial adviser. All potential percentage gains are based on from the low to the high of day.???????

 

 

 

Sincerely,

AST

 

 

 

 

 

 

Resources:

 

https://www.barchart.com/stocks/quotes/MOLOF/overview

 

https://www.otcmarkets.com/stock/MOLOF/overview

 

https://www.forbes.com/sites/davidblackmon/2018/01/29/the-oil-and-gas-situation-trumps-american-energy-dominance-agenda-becoming-realty/#11bde048676b

 

https://www.thebalance.com/oil-price-forecast-3306219

 

Disclaimer:

We have  received three thsnd dlrs via a bank wire  for the awareness of MOLOF





All of the information in this blog is gathered from public information released by the company.

By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this report. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.



We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

 

Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

 

LITH IS A TRIPLE THREAT WITH LITHIUM, MARIJUANA & BLOCKCHAIN
AND THEIR OWN COIN ON THE AGENDA

Kaboom Coin provides the underserved legal marijuana industry with decentralized
banking infrastructure, blockchain based consumer databasing and a payment solution.
 

LITH is a company operating in 3 hot sectors right now.

They operate in 3 disruptive industries/technologies:

1. Lithium – with the rise of battery operated vehicles and Tesla’s Gigafactory (as well as other skyrocketing needs
   or Lithium across numerous industries like energy storage), the current Lithium supply falls far short of the
   upcoming demand and we’re seeing a “battery miner” boon for Lithium companies.
    
2. MJ – Experts say the the MJ industry is heading to $24 Billion by 2025. An increase in support and with additional
   states passing MJ, the industry is exploding right now… and we’re seeing MJ stocks skyrocket again.
    
3. Cryptocurrency – The Cryptocurrency Market Cap Can Exceed $200 Billion by the End of 2017!

LITH is the only company we’re aware of with operations in ALL THREE of these world-changing industries!                                                

FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) Generates Leads, Marketing and Audience Insights to drive revenues and earnings

Lead generation is one of the primary problems affecting companies trying to attain exponential growth. Through FanLogic Connect, companies would be able to drive revenue and cut costs, while boosting profitability. FanLogic would drive direct sales through the use of contests to boost the bottom line. Consequently, this would outstandingly improve ROI for marketing, compared to traditional techniques.

FanLogic’s real-time contest reporting empowers clients and provides accessibility to specific daily contest information to summarize key metrics influencing the success of contests.

The metrics include:

• “Automated data collection at every point of the contest entry process
• Real-time, contest specific data to effectively manage campaigns, client reporting and measure effectiveness
• Lists of registered participants at the completion of a campaign
• Aggregation of registered participants to a central database for selective remarketing usage
• “Hooks” allow for secondary revenue streams (ads in registration pages, text links in follow up emails) Integration into existing personal relationship networks such as Facebook, LinkedIn, Twitter, etc. to enable those networks to spread our clients’ messages faster and more effectively”

Source: FanLogic

Another problem with the traditional advertising industry is using data to find the right target audience. FanLogic Connect collects a wealth of data from contests including:

• Buying habits
• Income
• Circle of friends
• Interests
• Education level
• Location
• Status
• Age of friends and relatives

   

Rather than targeting advertisements with the data, FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC)
takes a unique approach by targeting contests. FanLogic is looking for users who would be motivated to enter
contests to win various prices ranging from cars to tickets to a show or sports event. Using deep data, FanLogic
allows companies to figure out how to target their campaigns to the right consumers.

FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) has multiple revenue streams and could benefit from
various industries such as: sports and entertainment, gaming, substantial brands and products, cannabis,
ad agencies, and hospitality, travel and tourism.

With the innovative and ingenious creation of FanLogic Connect, could attract new clients, potentially increasing
its revenues and earnings, which are generally key drivers of market capitalization growth.

Blockchain, Tokenization, Marketing and Loyalty Rewards Companies Have Been Hot.

Some blockchain related stocks have been skyrocketing, most notably Overstock.com (NASDAQ: OSTK), which had a bullish run up after it announced it would be implementing tokenization.

In under one month, OSTK moved up over 70% off of the tokenization news.

Hubspot Inc (NYSE: HUBS), which is in the same space as FanLogic, ended 2017 up over 80%, and ran up nearly 30% in December 2017 alone.       

Additonally, RetailMeNot was acquired for over $600M, over a 50% premium to its closing price when the deal was announced, in 2017.

If FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is able to execute and create its modern FanBlock.io platform, this could be the next stock in the blockchain, tokenization and advertising space to catch the markets’ eye.

The Bottom Line

The demand for blockchain and tokenization is abnormally high, and many companies are trying to get into the space and leverage the power of the technology. When applied to the advertising and marketing space, blockchain and tokenization has positive implications, potentially allowing companies to better target their campaigns.

FanLogic Interactive Inc. (OTCQB: FNNGF; TSX-V: FLGC) is one of the leaders in the digital promotions software space looking to implement blockchain technology and tokenization. Blockchain-related stocks, like Overstock, and marketing stocks, such as Hubspot, have had strong performances, and FNNGF could runup with its breakthrough platform.

STOCKTA HAS THIS ONE “BULLISH” WHILE BARCHART HAS THE CANADIAN SIDE A “STRONG BUY”!!!!

Assets grew over 75% in just 3 months!

Our last play worked out well.  It bounced back and was up 27% today and is still sitting nicely above the alert price.  It looks as though all the selling has gone away on that one and we expect it to move higher on any buying pressure.

Remember that we also gave you a MJ play back in October that just hit highs a few days ago that showed us 50%+.

There are a few hot industries out there right now.  If you could pick 5 that really stand out, Lithium would most definitely be in that conversation.

According to a report released today by Zion Market Research, the global lithium-ion battery market was about $31.1Bln in 2016 and is expected to reach $67.7Bln in 2022. More on lithium in a moment… first, a glance at tonight’s lithium play that already has Phase 1 & Phase 2 Drilling Program results.

What happened to our last lithium/cobalt play?

That is correct, it shot up way above level even traders thought would be the top resistance points.

With that being said, add FRSSF to you watch list

Want to see what a beautiful chart looks like:

StockTA’s “Overall: Bullish” Analysis: Bullish for All 3 Terms & Overall

Barchart’s 100% Green Opinion: All 13 Indicators are Green

Note: The StockTA analysis pictured and linked above is for Far Resources’ OTC symbol FRRSF. Because FRRSF is new to the OTC Barchart does not have an opinion yet, so the Barchart link above is for Far’s CSE symbol, FAT.

As you can see, it’s about as perfect as it gets – StockTA doesn’t even list Resistance, only support… and FRRSF is a heck of a lot more than just a pretty chart. According to their latest CSE filing (numbers in CDN):

– As of June 30th, Assets Total: $2,795,874

– In March of 2017 Assets Totaled: $1,586,415

That’s more than 76% growth in FRRSF’s Assets in just 3 months!

Lithium, an essential component in modern car batteries and battery-operated cars, is the future of transportation:

– China wants 5Mln electric cars on the road by 2020

– California plans to have 1.5 million “zero-emission vehicles” by 2025

– California lawmakers want to “ban the sale of new cars fueled by internal-combustion engines after 2040”

– Goldman-Sachs called lithium the “new gasoline”

$67.7Bln is a monster number that shows us the evidence of the current “Lithium Boom,” but it doesn’t tell us the whole story. You see, until very recently, lithium was mined by just 3 companies… 3 Very Big Companies… yet as large as they are, they’re not capable of mining the massive amounts of lithium needed to meet the skyrocketing demand.

This massive gap in supply vs demand – potentially a $30BLN gap – is being filled by small mining companies new to the lithium game; and any time a Small company finds itself in a Big situation… well, that pretty much exemplifies the companies we search for.

One of these companies, Far Resources Ltd (OTCMKTS: FRRSF)(CSE: FAT), is a bit ahead of the field in its lithium mining & assay efforts and has recently built a near-perfect chart that just can’t be ignored:

Far Resources Ltd.

(OTCMKTS: FRRSF)(CSE: FAT)

Website:

www.farresources.com

Quote:

American: OTC: FRRSF

Canadian: CSE: FAT

Investor Presentation:

Far Resources Presentation

Video:

October 26th Lithium Testing: Assay Results for 60 Rock Samples from the Zoro Lithium Property

In mining it’s not always what you have but where you have it, in many cases the location of your exploration will determine the viability of your operations. In the case of Far Resources Ltd. the location of their two options couldn’t be better situated.

According to the Fraser Institute, Manitoba- home to FRRSF’s Zoro Lithium Property, is ranked as the world’s second best jurisdiction for mining investment.

Additionally, the company’s second option is the Winston Property, a silver and gold property located in New Mexico, USA, which is also ranked in the top 25 mining jurisdictions in the world by the Fraser Institute.

We’ll look at the lithium property first, but keep this in mind:

According to a report by Zion Market Research, the global lithium-ion (Li-ion) battery market was valued at around USD 31.17 billion in 2016 and is expected to generate revenue of USD 67.70 billion by end of 2022 and growing at a CAGR of slightly above 13.70% over the forecast period.

Metals and minerals consultancy Roskill Information Services provides a base scenario for lithium consumption at 290,000 tons in 2020. However, that figure rises to a sizeably larger 420,000 tons in what it calls its “optimistic” scenario.

Zoro Lithium Property:

www.farresources.com/zoro-lithium-property

Situated in west-central Manitoba within the historic Snow Lake mining camp, the Zoro1 Claim covers a significant lithium pegmatite occurrence known as the “Principal Dyke”, it contains an historic “reserve” based on 1956 drilling of 1.8 million tonnes grading 1.4% Li2O to a depth of 305 m.

Recent news surrounding Zoro Lithium Property:

• Entered into an MOU with Quantum Resources Limited, an exploration company that has the right to earn an interest in the Thompson Brothers lithium project which is contiguous with Far Resource’s option
• As part of MOU. Both companies have agreed to exchange information and to work together to assess the viability and potential synergies of developing their lithium assets in Manitoba together over the course of a one-year period
• During the period of the MOU, the parties will explore the most efficacious way to work together to move their projects forward through a mutually beneficial agreement to both parties

Addressing this MOU, Keith Anderson, President and CEO of Far Resources, summed up the significance of the deal, stating, “I am excited about the potential that can be unlocked by working together with Quantum on our lithium projects in Manitoba. The MOU represents the possibility for operational synergies and development options that will benefit Far Resources and our shareholders. We will be actively proceeding to investigate these possibilities to the mutual benefit of all stakeholders.”

Assay Results Released November 27, 2017:

• Company prospectors collected 60 representative rock chip samples from historic trenches and pits in Dykes 2, 3 and 4. These samples were analyzed for multiple elements including lithium and related metals
• High grade lithium with maximum values of 1.42% and 2.71% Lithium Oxide (Li20) were documented from Dykes 2 and 4 respectively
• Results increase the number of known high grade lithium-bearing pegmatite dykes on the Zoro property thereby providing targets for upcoming diamond drilling

Commenting on the results, Anderson stated, “The number of significant lithium-bearing pegmatite dykes on the Zoro property continues to grow as our geoscientific data becomes available. Two prospecting teams are now on our newly acquired ground at Zoro to explore for new lithium-bearing pegmatite. We also anxiously await assay results from our recently completed drill program on Dyke 1.”

Now for the gold and silver option in New Mexico. Once more something to keep in mind:

TD Securities commodity analysts have expressed a bullish position for both gold and silver in their 2018 Global Outlook- saying “its trade recommendation for next year is to go long silver” while also expressing optimism for a steady climb in gold prices.

Famed investor Jim Rickards has stated he is not convinced the Fed will raise rates next month at its monetary policy meeting and if they don’t he maintains that gold prices could reach $10,000 an ounce.

Winston Property

Located in Sierra County, New Mexico the property includes the Little Granite Mine as well as the Ivanhoe-Emporia Mines

Video Detailing Winston Property

Little Granite Mine– a high grade, past-producing underground silver-gold mine located in the Black Range Mining District of New Mexico. The main structure hosts a low sulphidation epithermal quartz vein (similar to the high grade Midas and Sleeper mines in Nevada), which has been traced for over 500 feet by underground workings and exploration drilling

Exploration Plan

Phase 1 – $350,000

– Diamond Drilling, to verify historic drilling results

– Property Maintenance

– Improved Road Access

– Field Sampling

Phase 2 – $600,000

– Ground Geophysics

– Data Analysis, Research

– Geo Re-Interpretation

– Diamond Drilling

Ivanhoe-Emporia Mines– mines are past producers of gold and silver, with a decline of 370 feet.  They have potential for a large tonnage of lower grade, stockwork veins surrounding high-grade veins mined in the past

Project overview:

– Past producing gold-silver mine

– Main shaft to 384 feed depth

– 370ft decline

– Potential for large tonnage of lower grade, stock work veins surrounding high grade veins mined in the past

– Soil geochemistry and geophysical anomalies defined for follow-up when funds available.

Conclusion:

In the last three to four years we’ve personally spent more time researching lithium than any other industry. In an era of disruptive technologies and advancements, lithium is disrupting the automobile industry.

Take a moment to think about that – one of the world’s largest industries that has generated trillions over more than a century and created household name icons is being turned on its head!

And amongst the biggest winners of this “electric car revolution” is lithium.

So, to recap, here is the blockbuster we’re looking at tonight:

– FRRSF operates in one of the world’s hottest industry

– FRRSF’s chart is drop-dead gorgeous

– FRRSF already has quality drill results that are generating A LOT of attention

– FRRSF has started to move, closing today at $0.7686

– FRRSF has major assets on its books

– Volume is building – over 537K today

FRRSF closed today at $0.7686, just off the day’s high of $0.8061 – there could be more room to run tomorrow!

If you didn’t click on the Barchart link at the top, this is what you missed:

That is a lot of green; how much further can FRRSF continue on this epic run?

We’re looking at a ground floor situation that is already exploding.

Make sure you put FRRSF & FAT.CN are the top of your screen right away.

FRRSF closed at $0.7686 today.

Far Resources Canadian issue, CSE:FAT, closed today at $0.86 with 6,013,000 in volume – nearly 3 times its daily average.

Sincerely,

AST

Disclaimer:

We have received fifteen thsnd dlrs via a bank wire for the awereness of FRRSF.
  All of the information in this blog is gathered from public information released by the company.

By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.



We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

 

Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

Let’s face it, the injection experience for some doctors and patients is outdated, and the traditional syringe has been unchanged for nearly 160 years.

Even with improvements in the healthcare industry, hypodermic syringes have stayed the same.

Now, Milestone Scientific Inc. (NASDAQ:MLSS) is looking to change the game and committed to advancing the science of computer-controlled drug delivery system, offering efficiency and patient comfort gains for both the medical and dentistry fields.

Milestone Scientific (NASDAQ: MLSS) Company Profile

Milestone Scientific is a leading medical research and development (R&D) company that’s designing and patenting innovative injection technology. With Milestone’s innovative computer-controlled systems, medical and dentistry professionals are able to make efficient, precise and virtually painless injections, and could take a large portion of the traditional injections market share.

MLSS offers its revolutionary DPS Dynamic Pressure Sensing Technology, which aims to meet the needs of various subcutaneous, or under-the-skin, drug delivery injections and fluid aspiration. This groundbreaking technology enables healthcare professionals to attain a plethora of unique benefits, which cannot currently be accomplished with the traditional manual syringe. This technology is Mileston Scientific’s patented system that has been used in over 65M dental injections.

The DPS Dynamic Pressure Sensing Technology has innovative features, allowing medical professionals to: measure tissue density to identify the exact needle location, control the flow rate of fluid, and provide precise tactile control. In turn, patients are able to receive injections and fluid aspiration with less pain.

Milestone Scientific’s technology empowers clinicians to receive real-time continuous feedback as to the local tissue conditions during the injection process. With the real-time feedback, healthcare professionals are able to accurately differentiate and identify specific tissue types and anatomical locations, making subcutaneous drug delivery safer, more effective and easier, transforming the traditional injection market.

Milestone Scientific’s Product Line

Milestone Scientific currently has three featured products: The Wand, CompuFlo Epidural and CompuFlo Intra-Articular.

The Wand is a computer-assisted system for local anesthesia. The Wand is the market leader in injection technology, and it’s the first of its kind and the best in its class. That in mind, MLSS has first mover advantage in the space, and differentiates itself from companies offering traditional local anesthesia injections.

The benefits of The Wand Computer Assisted Anesthesia System include: patient satisfaction, a new marketing opportunity, less stress and more options and flexibility for dentists, and increased productivity due to its rapid onset. When dentists use this technology, patients are more comfortable and less anxious, and The Wand could eliminate collateral numbness, allowing patients to get on with their day without a numb face.

Dentists are already implementing this technology, and there are hundreds of dentists across the U.S. As more doctors adopt Milestone Scientific’s The Wand product, the company should generate higher revenues and earnings, which should boost the company’s stock price.

Milestone Scientific (NASDAQ:MLSS) also offers CompuFlo Epidural, a safe and effective way to administer epidurals using pressure-sensing technology, offering a multitude of benefits for both medical professionals and patients.

Medical professionals, specifically anesthesiologists, are able to use both hands to advance and direct the needle, as well as objectively confirm, in real time, the epidural space with 99% success on the first attempt.

Unlike traditional epidural injections, there’s a lower likelihood that doctors need to reposition needle over multiple attempts, benefitting patients. Moreover, CompuFlo Epidural offers the potential for a radiation-free solution for identifying the epidural space in pain management patients.

CompuFlo Epidural leverages Milestone Scientific’s patented DPS Dynamic Pressure Sensing Technology, which helps to differentiate tissue types for medical professionals via audio and visual feedback. Consequently, this leads to precise location guidance as the needle advances toward the intended injection area. This helps to reduce the number of required attempts to accurately identify the epidural space, potentially making the patient’s experience less painful.

MLSS announced in June 2017 that CompuFlo Epidural Computer Controlled Anesthesia System received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Based on both nonclinical and clinical tests that were conducted, Milestone Scientific demonstrated CompuFlo Epidural device’s safety, efficacy and performance, in relation to other legally marketed predicate devices.

According to former Milestone Scientific CEO Leonard Osser, “Looking ahead, we are now focused on reaching out to the top KOLs in the U.S., as we have been doing successfully across Europe. The CompuFlo® Epidural System’s ease of use allows use by medical professionals with varying levels of experience, which further drives the value proposition of this technology. In addition, due to what we see as the device’s add-on value proposition, we plan to seek reimbursement codes over and above those already in place for traditional epidural procedures.”

Not only that, but MLSS recently announced that its CompuFlo Epidural System was successfully utilized in over 500 epidural procedures, including pain management, and labor and delivery. The CompuFlo Epidural System has been implemented in various settings at multiple leading institutions in Europe, South America, and the U.S.

MLSS Chairman and Interim CEO Leslie Bernhard stated, “Following our recent 510(k) clearance from the U.S. Food and Drug Administration, I am pleased to report we are successfully executing our strategy of placing the CompuFlo® Epidural System with key opinion leaders in the U.S., Europe and around the world. To date, we have successfully completed over 500 procedures with zero complications. These results are particularly significant considering the potential risk factors associated with a traditional epidural procedure.”

Milestone Scientific’s CompuFlo Intra-Articular Instrument allows medical professionals to administer accurate joint injections, without the risk of radiation. Although the CompuFlo Intra-Articular Instrument is not available in the U.S. yet, the company could file for FDA approval in the U.S., and if it’s able to receive approval for this product, MLSS could see further growth in its revenue and earnings, potentially driving the stock higher.

Now, there are numerous benefits for medical professionals and patients. The CompuFlo Intra-Articular Instrument provide medical professionals with:

• Precise computerized injection and drug delivery accuracy
• Needle deflection prevention
• Portable, reliable, versatile technology
• Lightweight and easy to use with two power sources, a standard AC plug, as well as a built-in lithium-ion battery pack
• 1 USB 2.0 port located on the rear off the instrument for allowing transfer of patient files in a .csv format for permanent storage

Additionally, CompuFlo Intra-Articular is designed to regulate the flow of fluid in order to reduce patient discomfort.

Milestone Scientific Could Tap into the Billion Dollar Syringe Market

There are a plethora of markets that Milestone Scientific could take a large portion of. According to Grand View Research, the global disposable syringes market size was valued at $6.4B in 2015, and this market is expected to grow due to the increasing demand for injectable drugs. By 2024, the global disposable syringes market is expected to reach $9.9B.

Additionally, according to Markets and Markets Research the prefilled syringes market is expected to reach $6.36B by 2021, from $3.93B in 2016, or a compound annual growth rate of 10.1% for the forecast period.

Not only that, but Grand View Market Research also projects the U.S. smart syringes market to grow to more than $3B by 2024, from just over $1.5B in 2015.

Milestone Scientific’s Competitors Are Thriving, and They Could Look to Acquire MLSS

Baxter International (BAX) is one of Milestone Scientific’s competitors, and it could look to acquire MLSS.

BAX has seen a strong rise in its stock price since the beginning of 2017, growing nearly 30% year to date.

Illumina Inc. (ILMN), another competitor of MLSS, has also seen some strength, rising over 55% year to date.

As more healthcare professionals shift towards Milestone Scientific’s products, MLSS could take a large chunk of the market share from its competitors. Additionally, this makes MLSS a potential acquisition target for large healthcare companies, due to its innovative and highly beneficial products.

With MLSS competitors growing significantly in market value, they could look to acquire MLSS for its technology, rather than conducting R&D and spending billions of dollars to try to develop technology similar to that of MLSS.

Final Thoughts

Milestone Scientific has over 20 patents, and its changing the way healthcare professionals provide injections to patients. With The Wand, CompuFlo Epidural and CompuFlo Intra-Articular, MLSS is well positioned to take market share from its competitors, in the injections and syringes markets.

With MLSS receiving 510(k) FDA clearance for CompuFlo Epidural Instrument, as well as the company’s announcement of more than 500 successful procedures using the system, competitors and investors might start taking notice of the growth potential in Milestone Scientific. Additionally, the patented DPS Dynamic Pressure Sensing Technology has been used in 65M dental injections, and once more dentists and doctors adopt this system, there should be a strong rise in MLSS sales and earnings, which are some of key drivers of the stock.

MLSS has a compelling story and is innovating the way medical professionals conduct injections, and it seems like it’s one catalyst away from a large move, to the upside. Investors and traders who want exposure to the micro-cap healthcare market may want to consider MLSS due to its growing presence in the traditional injections market.

Source:

1. https://www.milestonescientific.com/about
2. https://www.milestonescientific.com/about/dps-technology
3. https://www.milestonescientific.com/products/the-wand
4. https://www.milestonescientific.com/products/compuflo-epidural
5. https://www.milestonescientific.com/products/compuflo-intra-articular
6. http://www.grandviewresearch.com/industry-analysis/disposable-syringes-market
7. https://ir.milestonescientific.com/press-releases/detail/234/milestone-scientific-announces-510k-fda-clearance-for
8. https://www.prnewswire.com/news-releases/disposable-syringes-market-size-to-reach-usd-99-billion-by-2024-grand-view-research-inc-607568056.html
9. http://www.grandviewresearch.com/industry-analysis/smart-syringes-market
10. http://www.marketsandmarkets.com/Market-Reports/prefilled-syringes-market-16618331.html
11. https://ir.milestonescientific.com/press-releases/detail/248/milestone-scientific-announces-over-500-successful

Sincerely,

AST

Disclaimer:

We have received five thsnd dlrs via a bank wire for the awereness of MLSS.
  All of the information in this blog is gathered from public information released by the company.

By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.



We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

 

Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

I have to say it was a small shock to me that the major brands in the food sector have not focused their attention on night time snacking. Yes there are a few semi healthy options, but nothing in comparison in taste and satisfaction as day time ones provide.

Or, perhaps the big players are waiting for a small cap to create the market, achieve proof of concept which kicks off talks of a buy out or licensing, its a cheaper way for the big players to make sure they don't end up walking into a sector that may not work.

Well, NGTF has done a fantastic job of placing its stake in the night time snack industry just as its most needed given the rise of the Medical Marijuana sector; the munchies, a side effect that drives
an entire industry……think about it.

Some interesting information I found during my search:
 

Sincerely,

AST

Disclaimer:
We have received five thsnd dlrs via a bank wire for the awareness of NGTF.
We have previously received twenty thsnd drls via a bank wire for the awareness of NGTF which has since expired.
 

All of the information in this blog is gathered from public information released by the company.

By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.



We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.An

Any copywriting or redistribution of this article in any shape or form is not allowed without the written concent of the sites owners.
 

MOCI On a Path to Disrupt Global Media Production and Distribution

As the third quarter winds down, market participants are beginning to see a move toward a diffusion of capital by larger fund managers. Higher nominal growth in the global economy is sparking a rotation trade out of mega-cap technology stocks like Facebook (FB), Google (GOOGL), and Amazon (AMZN). And rumors of a tax reform bill hitting the wires has fueled a rush of those funds into domestic, high-beta stocks.

That means: small caps and micro-caps are on the move again.

The river of money coming into these market segments will be looking for two things: a good story and an undervalued position relative to a big end market. As far as we can see, MOCI is as attractive as anything out there from that perspective. However, this company is more than just another pretty face value setup: these guys are up to something that could be a unique and valuable innovation a market segment with virtually no pure-play competition.

The game is the coordination and development of a new model of market-based funding mechanisms supporting independent cinematic media that explicitly targets underserved emerging markets. It’s fascinating, and it might be hugely lucrative as well.

Quick Facts:

• MOCICEO Ross Cooper is one of the most experienced guys in the industry, with three decades in the game.
• MOCIalready owns a successful Chinese film fund and is looking to expand its operational reach and investments in emerging markets worldwide.
• MOCIhas begun to crusade for a new process to manage and view mobile video, with an innovative exchange model to network together financing from .
• MOCIis an emerging leader in the nearly $80B mobile app space.
• MOCIis coming off an RSI trough under 45, pointing to a massively oversold stock now heading back the other way.
• MOCIjust recorded a MACD Bullish reversal, suggesting a technical change in trend.
• MOCIis knocking on a potential technical breakout that could occur on a surge above the 200-day simple moving average at $0.95. The stock recently broke out above its 50-day SMA earlier this year, and has held those gains.

Understanding the Basic Story

Modern Cinema Group Inc. (OTCMKTS:MOCI)is gearing up, as far as we can see through our research, to disrupt the business of film making. This is a new kind of Hollywood studio. The emphasis is on creating a new model for how movies and television shows are financed as the modern content-sphere becomes an increasingly global phenomenon.

If you set out to make a new film, you may need to go affiliate with a major production house and they will work with you to pitch to investors and fund the production if the project makes business sense.

That’s the way it is currently done, and has been done for a long time.

MOCI is looking to change all of that. That model doesn’t work if you have a project that could really work in the emerging world. The fundraising step is where the operation breaks down. However, MOCI is working on a model that borrows from the mechanisms inherent in the functioning of futures exchanges to distribute the weight of the financing process among self-interested and unconnected speculators.

If the model gets traction, it could truly revolutionize not only how films and TV series are financed, but also the range of projects that can be seen as economically viable in the first place. This last point is critical to fostering a burgeoning media consumer culture in market territories such as Asia, Europe, Africa and South America. But, whoever solves that puzzle could potentially capture and have direct connection to over 50% of the world's population. So this is Big Game stuff.

That brings us to another point of strength: The company’s CEO is Ross Cooper, a man with 30 years of experience as a successful entrepreneur and corporate officer. According to the company’s materials, Mr. Cooper is also an accomplished inventor with numerous patents to his name.

From what we can see, Cooper has been an innovator throughout his career and continues to find avenues that provide an edge. He has a few exits already as an entrepreneur and managed to entrench himself in the fabric of Hollywood as the Executive Producer for movie, television and music projects.

Mr. Cooper has been responsible for the creation and operation of many companies in the areas of Media & Entertainment, Education, Psychometrics and Health Sciences.  Mr. Cooper is currently negotiating the rights to his original story named “Wingman”.

Now, he leads this new effort to exploit the virgin territory of emerging market dynamic media content financing and distribution. According to company materials, MOCI has numerous divisions that provide novel and timely solutions with the ultimate goal of building a worldwide dominant motion picture network. Right now, Modern Cinema Group provides libraries of movies, television and game content to large population groups by way of its distribution partners (primarily mobile carriers).

During the summer of 2014, Modern Cinema opened a film (and media) financing fund within the Free-Trade located in Shanghai China before these types of funds were closed to foreign entities.

Since China is now the largest market for filmed entertainment, and media investments in China are highly attractive to the numerous funds; Modern Cinema Group is well positioned to either finance or co-finance productions along with Chinese entities (both private and corporate). Modern Cinema plans to begin Chinese Co-Productions in early 2018.

One of the company’s primary insights is a focus on “pre-positioning” media content, where users are able to gain on-demand access to content actually stored locally on the device. This circumnavigates one of the primary hurdles to consumer experience of media where infrastructural resources are second- or third-tier.

With this in mind, one can imagine that MOCI execs are targeting the 2018 World Cup as a major breakout point for the business: nothing is more core for emerging market media engagement than the World Cup. And this is exactly when mobile carriers will need to increase efficiencies as these games will introduce unprecedented demands on mobile networks in Latin America, Europe and Asia. Modern Cinema Group and its partners are working to secure opportunities for the World Cup now.
 

A Brave New World

The move to focus on emerging markets is itself enormously compelling precisely because the niche offers a mouth-watering combination of low-competition and high potential growth over time. The only hurdle is the technological barrier to entry: the reason why competition is low is because the economics normally don’t favor targeting media towards emerging markets given that costs of production and distribution may be higher and revenues from things like advertising are normally going to be quite a bit lower. So, the ROI simply isn’t there.

That is true unless you start with a new model for both financing projects and distributing media. That appears to be exactly where the MOCI story is going. With a diversified funding draw model and an ability to drive high-quality locally-relevant media content to consumers operating on older (3G and 4G) mobile networks with major delays or buffering obstacles is the holy grail. And it would appear that Cooper has his team on tract to make a run at this outcome through Multicasting using MBMS. Newer LTE networks will use eMBMS or LTE Broadcasting.

As the company’s materials explain, this allows both older 3G/4G and newer LTE networks to potentially send our content to millions of user devices simultaneously.  The content titles will be stored on user’s devices to be played at a later time (On-Demand) — the Pre-Positioning methodology we covered earlier.

According to the company’s website, MOCI Media is already in contract negotiations with mobile carriers located around the world.

Technical Analysis

As it stands, the stock has been increasingly showing signs of a being in a new and burgeoning bullish trend: we saw a clear bullish breakout above its 50-day simple moving average in June on a bullish inflection in the MACD indicator.

Those gains have been preserved, and the stock is now clearly knocking on the door of a similar breakout above its 200-day SMA as well. That could push shares above the key psychological marker at the $1/share level.

All of this has happened ahead of a planned surge in investor relations noted by management as a next step, suggesting that we are sitting in front of a positive technical feedback loop with major implications.

About MOCI

MOCI (Modern Cinema Group Inc.) is a new Hollywood studio “disrupting the way movies and television series are financed in the new Golden Age of Content Everywhere.”

Based in Beverly Hills, founded in San Diego, the company has a decidedly technological spin on how to finance movies by allowing the world's largest Multichannel Video Program Distributors (primarily Cable and Satellite Operators) to compete with on-line services by offering their own branded Hollywood movies and television series. The production budgets for movies being between $40 million and $100 million. Budgets for television series in the range of $100 million per season. Financing partnerships currently in place with numerous Chinese Film funds.

Sincerely,

AST

Disclaimer:
We have received five thousand dollars via a bank wire for the awareness of MOCI.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

Following our enormous win the junior gold mining space earlier this month, we are now ready to turn our attention to another market segment that offers the potential for home runs and grand slams on a regular basis: biotechnology.

Now lets research OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). And, fortunately, it’s not a difficult study: there’s a ton to like here right now, particularly following the company’s most recent announcement detailing its success in its Phase Ia trial for its lead pipeline asset, ProscaVax, which is now heading into a Phase II study with momentum and promise, and toward the $7B prostate cancer market.

But OBMP is not as simple as the ProscaVax story. In recent months, under the leadership of its …., the company has diversified widely with the goal of funding future operations and R&D through actual revenues rather than hopes, promises, and dilution, which is the more common path for early-stage biopharma plays. That’s our focus today: why this company is different.

Quick Facts:

• OBMP has a small trading float of just 9.8M shares, which suggests the stock could launch higher on any additional influx of interest.
• OBMP has a lead drug candidate heading into the possible commencement of critical Phase 2 trials in the $7B prostate cancer space, with phase one now well sorted out.
• OBMP acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH over the Summer. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.
• OBMP also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.
• OBMP is working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.
• OBMP management recently noted that the company had a total of 48 drugs/drug candidates that “are already under our control for specific markets or are the subject of negotiations.”
• OBMP is one of the most diversified biopharma microcaps on the OTC today, with an enormous array of revenue paths set to hit over coming quarters.

Understanding the Basic Story

OncBioMune has too often been lumped into the one-horse prostate cancer lotto as a shorthand way to understand the company. And that has misled longer-term shareholders into giving up on the story, which is perhaps the most compelling reason for new investors to take notice and give this stock a fresh appraisal. The critical factor in understanding exactly why that one-horse prostate cancer lotto story is wrong is the company’s process of intense diversification in its top-line potential over the past 6 months. In that time, we have seen one announcement after another that all focus on the same narrative: marketing and distribution rights to therapies that have commercial viability now.

The story really started with the acquisition of Vitel Laboratorios, S.A. de C.V, which got the
ball rolling for sales in Mexico of the Company’s licensed products, Bekunis for constipation
and Cirkused for stress. They both exceeded projections during the first six months on the
market and represented two commercially viable horses in the stable.

Sales from September 16, 2016 to February 16, 2017 were approximately $330K, exceeding
projections for $125K initially forecast for the first six months at product launch during the third
quarter last year. The Company anticipates that sales efforts will continue to accelerate and
anticipates combined sales in the range of US$750,000 to $850K for the products in 2017.

But that was just the beginning.

Just after the Vitel move, OBMP execs pulled off another similar move, announcing the signing of a licensing agreement between the Company and PROCAPS S.A.S. granting OncBioMune rights to tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL), throughout Mexico, Central America and Latin America.

That was followed by the company’s announcement of an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH, a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.

OncBioMune and AqVida are currently conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.

Rather remarkably, the blitz toward commerce and revenues did not end there.

The company recently announced that it has formally acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.

In this string of strategic moves, one might easily have overlooked yet another move tucked into the middle of Summer, when the company announced that it is now working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.

Most recently, in an interesting move, the company has also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.

The Revenue Train

Hence, this is far, far more than just an early stage R&D play in the prostate cancer space. This is quite possibly the preeminent rising biopharma play in the Mexican and Latin American markets, with commercially viable revenue streams taking root in markets as diverse as Stress, Constipation, Rabies, AAT, Cancer, and Leukemia.

The moves are already starting to pay off. The company announced sequential top-line Q2 growth of 935%. That type of number should send a flare up to momentum investors if the stock starts to establish some newfound momentum on the chart.

We are coming into the end of Q3, and folks are sure to start to pricing in another major jump in sales. But the real remarkable point might come into year-end, when several of the company’s newest horses start to leave the stable and join the race, such as the six new products it will begin commercializing in Mexico in Q4 as part of its roha partnership deal.

However, perhaps the most interesting story is the mysterious AAT deficiency opportunity recently alluded to in company communications. Management is being a little cagey about the details for competitive reasons, but they are not being coy about its market potential.

“This is absolutely a blue ocean opportunity for us that could generate tens of millions of dollars in high-margin revenue by helping just a small portion of patients with AAT deficiency in Mexico. The first patient’s private insurance has already agreed to reimbursement, a positive sign for us moving forward,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Patients with AAT deficiency need to know that they have the disorder as soon as possible, information that could potentially lower the risk of developing life-threatening diseases by early intervention. We are optimistic that we will successfully negotiate the licensing agreement and fill this area of unmet medical need in Mexico.”

AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually. That’s where the “tens of millions in high-margin revenue” notion comes from.Any way you slice the OBMP story right now, you get further and further away from the typical “one-horse, pre-revenue biotech betting it all on a long-shot.” This is strategically diverse commercial-stage organization with 48 horses in the stable and a radical top-line revenue growth acceleration that has already begun.

ProscaVax
 

That said, the biggest horse in the stable is still its prostate cancer ticket, ProscaVax.

The drug recently completed a Phase 1-a study with strong results. The study enrolled 20 biochemically progressing prostate cancer patients, four of which dropped out due to disease progression (3 with increasing PSA, 1 radiological).

Perhaps even more interestingly, the study further evaluated secondary objectives that could suggest efficacy for ProscaVax having a meaningful benefit in treating late-stage prostate cancer. According to the company, “At a median follow-up of 31 months post-final vaccination, 9 of the 14 evaluable patients (64.3%) who received all six vaccinations had increased PSA doubling time, suggesting ProscaVax was slowing tumor growth. 12 of 15 patients (80.0%) completing the protocol had an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay.”

That is basically the ideal outcome for a Phase 1 study: no toxicity, but indications of a therapeutic benefit. From here, we will likely now see the company release full details of the plan going forward, including the outline of its upcoming Phase 2 research on the drug.

As noted above, the prostate cancer market is massive, with over $7B in total sales on the line. If the market begins to take ProscaVax seriously – as a real contender in this space – then we could be looking at a massive repricing of OBMP shares. The successful closing of its Phase 1 study puts that on the table going forward.

About OBMP

OBMP (OncBioMune Pharmaceuticals Inc.) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products.The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. The company also has a portfolio of targeted therapies for international marketing and is headquartered in Baton Rouge, Louisiana.

Disclaimer:
We have received five thsnd dollars via a bank wire for the awareness of OBMP.
We have previously received five thsnd dlrs via a bank wire for the awareness of OBMP which has since expired.

All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.